Better Together – Merck KGaA Announces Collaboration with Artios

Merck KGaA and Artios Pharma Limited announced today that they have entered a strategic collaboration agreement to discover and develop multiple precision oncology drugs over the course of the next three years. Under the terms of the agreement, Artios will receive a payment of $30 million in the form of an upfront and near-term payments. The company may also be eligible to receive up to $860 million per target, if Merck KGaA chooses to exercise the option.